Business Context and Reporting Period
This Form 8-K reports on the results of the 2019 Annual Meeting of Stockholders held by Neuralstem, Inc. on June 12, 2019. The filing was submitted on June 18, 2019. Note: The request metadata references "Palisade Bio, Inc.," but the filing text explicitly identifies the registrant as Neuralstem, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
As of the record date (April 26, 2019), 20,013,436 shares were outstanding, with 16,108,502 shares represented at the meeting. The following proposals were approved:
- Proposal 1 (Director Election): William Oldaker was elected as a Class II Director for a three-year term.
- Proposal 2 (Auditor Ratification): Dixon Hughes Goodman was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Proposal 3 (Stock Issuance): Stockholders approved the issuance of more than 20% of issued and outstanding common stock to Tianjin Pharmaceuticals Group International Holdings Co., Ltd. to comply with NASDAQ Marketplace Rule 5635(b).
- Proposal 4 (Reverse Stock Split): Stockholders authorized the Board to effect a reverse stock split of common stock by a ratio of not less than 1-for-2 and not more than 1-for-25 at its discretion within one year.
- Proposal 5 (Equity Plan): The Neuralstem 2019 Equity Incentive Plan was adopted.
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, management commentary on future outlook, or detailed risk factors beyond the authorization of a potential reverse stock split, which implies a need to maintain compliance with listing standards.
Key Facts for Investor Verification
- Verify the exact ratio and timing of the authorized reverse stock split (1-for-2 to 1-for-25) as determined by the Board.
- Confirm the terms and impact of the stock issuance to Tianjin Pharmaceuticals Group International Holdings Co., Ltd.
- Review the details of the newly adopted 2019 Equity Incentive Plan for potential dilution effects.
- Monitor the company's compliance with NASDAQ listing requirements following the approved actions.